Get the Stockscreener App
8.65
0.70%
0.06
After Hours:
8.80
0.15
+1.73%
Bioage Labs Inc stock is traded at $8.65, with a volume of 190.24K.
It is up +0.70% in the last 24 hours and up +63.21% over the past month.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
See More
Previous Close:
$8.59
Open:
$8.59
24h Volume:
190.24K
Relative Volume:
0.60
Market Cap:
$310.15M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+10.90%
1M Performance:
+63.21%
6M Performance:
+121.79%
1Y Performance:
-53.09%
1-Day Range:
$8.44
$8.99
1-Week Range:
$7.84
$8.99
52-Week Range:
$2.88
$20.37
Bioage Labs Inc Stock (BIOA) Company Profile
Name
Bioage Labs Inc
Sector
Phone
510-806-1445
Address
5885 HOLLIS STREET, EMERYVILLE
Compare BIOA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
8.65 | 307.99M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
122.06 | 51.07B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.30 | 44.42B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.87 | 42.75B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.21 | 27.86B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
474.82 | 20.44B | 3.08B | 1.24B | 1.07B | 25.61 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-22-25 | Upgrade | Citigroup | Neutral → Buy |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Dec-10-24 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Dec-09-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Oct-21-24 | Initiated | Citigroup | Buy |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-21-24 | Initiated | Morgan Stanley | Overweight |
View All
Bioage Labs Inc Stock (BIOA) Latest News
Is BioAge Labs Inc a good long term investmentCapital Gains Strategies & Small Budget Portfolio Growth - earlytimes.in
BioAge stock craters 70% on obesity drug study halt (update) - MSN
Is BioAge Labs Inc. (Y7G) stock supported by free cash flowPortfolio Growth Summary & Weekly Chart Analysis and Trade Guides - newser.com
Is BioAge Labs Inc. stock recession proofStop Loss & Free Weekly Watchlist of Top Performers - newser.com
Will BioAge Labs Inc. (Y7G) stock hit analyst forecastsBuy Signal & Expert Curated Trade Ideas - newser.com
Is BioAge Labs Inc. (Y7G) stock a buy on weakness2025 Short Interest & Risk Adjusted Buy and Sell Alerts - newser.com
How interest rate cuts could boost BioAge Labs Inc. stock2025 Earnings Impact & Accurate Intraday Trading Signals - newser.com
Is BioAge Labs Inc. stock a buy before product launchesMarket Volume Report & Weekly Top Stock Performers List - newser.com
How supply shortages influence BioAge Labs Inc. (Y7G) stockWeekly Volume Report & Accurate Entry and Exit Point Alerts - newser.com
How to use Fibonacci retracement on BioAge Labs Inc.Gap Up & Verified Stock Trade Ideas - newser.com
Order flow analysis tools used on BioAge Labs Inc.Entry Point & Low Risk Entry Point Tips - newser.com
Will BioAge Labs Inc. (Y7G) stock sustain uptrend momentumTrade Analysis Report & Daily Risk Controlled Trade Plans - newser.com
How BioAge Labs Inc. (Y7G) stock stacks up against competitorsQuarterly Portfolio Report & Safe Capital Growth Tips - newser.com
Top 3 Biotech Stocks Capitalizing on the AI Revolution - Investing.com India
BIOA: NLRP3 inhibitor targets cardiovascular risk in obesity; APJ agonist INDs planned next year - TradingView
BioAge Labs (BIOA) Price Target Increased by 20.83% to 9.86 - Nasdaq
BioAge Labs Inc. stock trendline breakdownGold Moves & Fast Entry Momentum Trade Alerts - newser.com
Bioage Labs Inc Stock (BIOA) Financials Data
There is no financial data for Bioage Labs Inc (BIOA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):